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Abstract 
Assessing the value of new medical technologies may require new approaches that take into 
account a more comprehensive set of parameters than the incremental cost/QALY. It is 
argued that MCDA can fulfil this role and has the potential to be methodologically superior 
to the currently used approaches mainly because of receiving input from multiple, and 
seemingly relevant criteria or parameters, thus forming a more holistic approach to assessing 
overall value. Inclusion, scoring and weighting of these parameters would be based on the 
expertise and opinion of a much wider spectrum of stakeholders involved, thus aiming to 
achieve an optimal balance across different, and probably opposing, interests. The MCDA 
score reflecting the overall value of a new medical technology would then be linked to 
coverage and/or pricing decisions. Coverage decisions could adopt a value for money 
approach that considers both value and cost of options based on an enhanced cost-
effectiveness paradigm. Alternatively, for price-setting purposes, a pre-determined link 
between scores and prices would be needed; however, such a link would be country- and 
context-specific for each assessment case. Either way, any coverage and/or pricing decision 
would need to reflect the value as received by the different stakeholders and in relation to a 
wide range of criteria. 
 
Keywords: multiple criteria decision analysis; value-based pricing; cost effectiveness; 
medical technology; pharmaceuticals; HTA 
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1. Background 
Technological advancements in combination with higher life expectancy, higher patient 
expectations, and increased prevalence of chronic diseases, have led to significant increases 
in public spending on pharmaceuticals, which, on average account for 17% of total health 
expenditure or about 1.6% of GDP across OECD countries (OECD, 2012). Given the 
resources governments and health systems can spend on healthcare, the pathway to optimal 
resource allocation passes through cost containment and efficiency improvement policies.  
At the other end of the spectrum scientific advances often require significant risk-taking and 
research and development (R&D) investment and are usually rewarded via the intellectual 
property system. Although patent-induced monopolies may be associated with market 
inefficiency (Baker and Chatani, 2002; Hollis, 2004) they have been accepted as a necessary 
trade-off for social welfare enhancement through the advance of scientific innovation. 
The above create a crucial trade-off in achieving a balance between the potentially conflicting 
interests of health policy and industrial policy goals, or static efficiency (optimal allocation at 
a point in time) and dynamic efficiency (efficient allocation over time) respectively (Sloan 
and Hsieh, 2007; McGuire et al, 2009). 
 
2. Transition to a Value Based Pricing Framework 
An increasing proportion of new medicines are associated with a high monetary cost but also 
with a high degree of uncertainty on their additional value. In the context of value assessment 
for new medical technologies, current Health Technology Assessment (HTA) approaches 
examine the clinical efficacy of new medicines in combination with or without their cost-
effectiveness, while increasingly incorporating real world post-marketing authorisation 
evidence, to incorporate comparative effectiveness and efficiency (Kanavos et al, 2010).  
However, these approaches are limited by significant subjectivity in the process of criteria 
selection for interpreting evidence and determining value, including what metrics to use for 
measuring efficacy/effectiveness, what types of costs to consider, and, very importantly, how 
to account for other key factors relating to overall value. 
The value of new medical technologies is multi-dimensional and not strictly limited to 
clinical benefit and monetary cost.  Many important factors affecting value such as the 
burden of disease the treatment addresses, aspects of the treatment’s innovation level, and its 
wider socioeconomic implications are not adequately reflected in the assessment process. 
Many of these value parameters are not always considered, and when they are it is only on an 
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implicit and non-systematic manner; thus the methodological framework these value 
assessment approaches are adopting is incomplete and at best partial. 
Following a number of criticisms of the current system of pharmaceutical regulation (OFT, 
2007; Kennedy, 2009; DH, 2010) the UK government announced a public consultation in 
2010, suggesting for the introduction of a new system of value based pricing (VBP) when the 
current PPRS agreement expires and inviting interested groups to submit views on the design 
of a new system that should “reflect the value of medicines and deliver best health outcomes 
for the people of the UK” (DH, 2010, p.6; Cabinet Office, 2010). The rationale was that the 
new system should take into account drugs’ real value to patients along their trajectory, thus 
providing better value for money for the NHS,  stronger incentives for socially desirable 
R&D and creating a more stable and sustainable investment environment (OFT, 2007; DH, 
2010).  
It was suggested that in addition to drugs’ incremental (quality-adjusted) therapeutic benefit 
(e.g. Quality Adjusted Life Years gained), relative to its incremental cost that currently many 
HTA approaches consider, other parameters related to burden of illness, therapeutic 
innovation and improvement, and wider societal benefits should also be explicitly 
incorporated in the assessment process. It was proposed that the cost-effectiveness threshold 
of the new medicines should be somehow weight-adjusted in order to reflect any of these 
additional elements, implying a higher range of threshold for medicines which tackle diseases 
with higher burden of illness, that demonstrate greater therapeutic innovation, and with wider 
societal benefits (DH, 2010); the rationale for assigning such a weighting system was 
subsequently contested by NICE due to methodological issues and double-counting 
considerations (NICE, 2011). 
The consultation that ensued on the subject attracted significant attention and received 188 
responses (DH, 2011) from a variety of stakeholders. Some among them suggested or implied 
the use of multi-criteria decision analysis (Kanavos et al, 2011; NICE, 2011) as a means of 
providing an enhanced analytical framework for the assessment of value. The Government 
response to the consultation confirmed that there was a clear majority supporting a transition 
towards VBP, and that it intends to better define how to represent value (DH, 2011). 
It is clear that a central aim of more recent approaches to value, including VBP, is to 
incorporate other factors into the valuation scheme. Multiple conflicting interests that need to 
be balanced out when placing a new medical technology on the market act as an additional 
reason why a wider perspective and assessment are needed.  No such “holistic” value based 
assessment framework has been successfully created yet.  
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3. Aggregating value categories into a composite metric of overall value: different 
approaches 
In order to capture the debate around different value parameters and their incorporation into a 
single metric that reflects overall value, different approaches exist, notably, a deliberative 
method, the net benefit approach, the weighted QALY approach and multiple criteria 
decision analysis. 
Deliberative methods are commonly described as a hybrid between consultation and research 
and aim to involve the public in decision‐making in a meaningful way; they include citizens’ 
juries, consensus conferences, deliberative workshops, deliberative polling and deliberative 
mapping (Yetim, 2009; Myant and Urquhart, 2009). While in some ways similar to 
qualitative research methods (e.g. focus groups), they provide an opportunity for participants 
to find out more about a topic, consider relevant evidence and discuss this evidence with 
other participants before presenting their view. While deliberative methods provide 
opportunities for the public to consider different options and make more informed decisions 
than is possible from traditional consultation methods, they suffer from significant 
disadvantages such as biases, lack of robust sampling strategies, and applicability of the 
results, among others (Myant and Urquhart, 2009).  
The net-benefit approach avoids the interpretation and statistical problems related to the 
incremental cost effectiveness ratio and implies a number of advantages (Zethraeus et al, 
2003). First, traditional statistical methods can be used for confidence-interval estimation and 
hypothesis testing. Second, calculation of the optimal sample size and the power of the study 
are facilitated allowing the correlation between costs and effects to vary within and between 
patient groups. Third, the use of a Bayesian approach to cost-effectiveness analysis is 
facilitated. Fourth, a formal relation between cost-effectiveness acceptability curves and 
statistical inference is provided. Finally, the net-benefit approach gives the Fieller's limits of 
the confidence interval for the incremental cost-effectiveness ratio in the cost-effectiveness 
plane. However, the net benefit approach has significant challenges, which may limit it 
general applicability; for example, it is difficult to estimate certain elements of value in 
monetary terms; in addition, there may be social/political unease with assigning a monetary 
value to health. 
The weighted QALY approach uses QALYs as the single measure of value, which is up-rated 
or down-rated with the use of weights to account for the elements of value. As already 
discussed, this can be a useful approach when the QALYs are a good (and proportional) 
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measure of value for the other elements (such as severity of the patient’s condition, etc.), 
nevertheless, not all elements of value can be measured directly in terms of QALYs gained 
(e.g. degree of innovation). 
In the context of Multiple Criteria Decision Analysis (MCDA), elements of value can be 
measured and scored in their natural units or through constructed scales, quantitatively or 
qualitatively, and weights are assigned to reflect criteria’s importance when combining them. 
This methodology may signal a departure from the cost per QALY gained approach and the 
cost-effectiveness threshold would potentially need to be recalculated into cost per additional 
point (where the point is the aggregated unit of value, possibly encompassing QALYs and 
any other measures involved). However, this approach may provide a more comprehensive 
account of value parameters, greater transparency in how multiple criteria are explicitly 
valued, weighted, and aggregated, and a more inclusive approach to stakeholder views on 
value.  
In turn, we are exploring how MCDA could offer an alternative method of valuing new 
medical technologies. 
 
4. Developing an MCDA Framework for Value Based Assessment of new medical 
technologies 
Decision analysis can provide an alternative way of measuring and eliciting value. In 
particular, MCDA “is both an approach and a set of techniques, with the goal of providing an 
overall ordering of options” by looking at the extent to which a set of objectives are achieved 
(Dodgson et al, 2009, p.46). It is a way of analysing complex situations characterised by a 
mix of objectives and does so by disaggregating a complex problem into simpler components, 
measuring the extent to which certain options achieve the objectives, weighting these 
objectives, and re-assembling the components to show a comprehensible overall picture 
(Raiffa, 1968; Dodgson et al, 2009).   
MCDA methodologies have been suggested for use in public services (Dodgson et al, 2009), 
including transport (Pearman et al, 1989; DETR, 1998). MCDA has been used, on an 
experimental basis, in order to assess the benefit-risk (clinical) profile of new medicines for 
the purpose of regulatory approval during marketing authorisation stage by the European 
Medicines Agency (Phillips et al, 2011) and others (Walker and Cone, 2004). Its use has also 
been suggested in health care and value assessment in HTA (Devlin and Sussex, 2011) also 
offering a conceptual framework (Goetghebeur et al, 2008).  
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The robustness in terms of the multiplicity of criteria that can be assigned to assess value, the 
flexibility in terms of the differential weights that can be applied to the different criteria, and 
the encompassing nature in terms of stakeholder inclusion suggest that MCDA can be applied 
in medical technology value assessment. Still, technical and methodological questions remain 
related to the details of the assessment process, including (a) the criteria of value that should 
be considered, (b) how can the weightings of the different elements be determined, (c) what 
should the involvement be of stakeholders and (d) how would the derived value translate into 
coverage and/or pricing decisions for the technology assessed. 
Although a variety of MCDA methodologies exist, the process of MCDA includes a number 
of common stages as follows (Dodgson et al, 2009): (a) establishing the decision context by 
defining the aims of the MDCA, and who the decision makers and other key stakeholders are; 
(b) identifying the relevant options; (c)  identifying the objectives and criteria that reflect the 
value associated with the consequences of each option; (d) “scoring” the value associated 
with the performance of each option against the criteria; (e) “weighting” each of the criteria 
to reflect their relative importance to the decision; (f) combining scores and weights for each 
option to derive the overall value; (g) examine the results; and (h) conducting a sensitivity 
analysis of the results to test the influence of changes in scores or weights. 
 
4.1. The decision context 
For the purpose of value-based assessment (VBA) of pharmaceuticals, the decision context 
could adopt a societal point of view that aims to maximise social welfare. Since MCDA 
would form a framework for the pricing of future and already marketed drugs, options (i.e. 
different drug candidates) might not altogether be known beforehand but would be introduced 
on a rolling basis.  
 
4.2. Deciding on criteria for value assessment 
Possibly the most fundamental step affecting the MCDA model would be to decide on the 
criteria for which the drugs would be scored against. These criteria, or grading parameters, 
would represent factors that are important when assessing the “value” of a drug in a VBA 
context, and would be chosen through a literature review, possibly accompanied by experts’ 
opinions collected through questionnaires and/or group meetings.   
They would include several drug – disease vital characteristics that could be divided in 4 
main clusters: (a) burden of illness, (b) therapeutic impact, (c) innovation level, and (d) 
socioeconomic impact. These clusters would form the higher or top-level criteria groups 
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where the most important trade-offs take place, made up from a number of more specific 
lower or sub-level criteria whose hierarchical representation would take the form of a value 
decision tree, such as ValueVectorTM, as shown in Figure 1.  
 
Figure 1 
ValueVectorTM: An MCDA tree for Value Based Assessment of new medical 
technologies (1),(2)  
 
 
 
Notes:  (1) ValueVectorTM is a value framework based on MCDA principles developed by the 
authors of this paper.  
(2) This figure provides a brief account for ValueVectorTM; for further information 
please enquire with the authors. 
Source: The authors. 
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“Burden of illness” would include criteria related to the size of the patient population being 
affected, the severity of the disease and the current unmet clinical need. “Therapeutic impact” 
would include clinical criteria mainly associated with the efficacy/effectiveness (e.g. direct 
and clinically meaningful endpoints including quality of life benefits, indirect and surrogate 
endpoints) and the safety and tolerability (adverse drug events and contra-indications) of the 
treatment; essentially, these criteria would rate technologies based on whether they provide 
significant added therapeutic benefit or a cure, moderate therapeutic benefit or modest 
therapeutic benefit. “Innovation level” criteria would classify the technology based on the 
nature of innovation it incorporates (e.g. whether it is breakthrough or a follow-on); it could 
also consider its Anatomical Therapeutic Chemical classification, the existence of any “spill-
over” innovation effects, and other non-typical secondary types of innovation. Finally, 
“socioeconomic impact” would refer to any broader societal public health benefits and the 
impact on direct and indirect costs, including non-medical costs and loss of productivity, both 
for patients and carers.  
In structuring and exemplifying the clusters and the specific criteria in ValueVectorTM, we 
ensure that the resulting model is parsimonious and that the criteria and the dimensions 
considered are not overlapping with each other. 
 
4.3. Assigning scores for each option  
The second most influential step after deciding on the criteria would be assigning the 
expected consequences for each criterion attribute (e.g. % of population affected by the 
disease, for the population size criterion) - on the X-axis, with a numerical “preference” or 
“utility” relative score - on the Y-axis, thus creating “value-functions” that can be used to 
convert criteria consequences into scores that are comparable. Typically, such a scale could 
range from 0 to 100, where 0 would represent “a real or hypothetical least preferred option”, 
and 100 would represent “a real or hypothetical most preferred option”, thus more preferred 
options would score higher and less preferred options would score less. Each option would 
subsequently be scored against each criterion, yielding the corresponding “preference” 
scores.  
“Value-functions”, either in linear or non-linear form, could be constructed using key 
stakeholder and expert (e.g. clinical professionals, public health specialists, government 
officials, HTA regulators, industry representatives, and patient advocates) opinions collected 
through facilitated workshop(s) or study session(s) as part of “decision conferences” (Phillips 
2007; Walker et al., 2011; Phillips et al., 2011).  Such an approach that uses the judgment of 
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expert(s) to associate a value number, possibly in a 0–100 range, with the attribute’s input 
(performance) of that criterion is known as direct rating (Dodgson et al., 2009); alternatively, 
if it is difficult to directly allocate scores, perhaps because the criterion is weakly defined or it 
reflects a complex concept, indirect scoring approaches could also be used such as the 
bisection method and various difference methods (Belton and Stewart, 2002). 
 
4.4. Assigning weights to each criterion  
The next most important step would be assigning a weight on each criterion, reflecting its 
relative importance to the overall valuation of the drug. For example, in terms of the “burden 
of illness” cluster of criteria, if severity of the disease was to be considered twice as 
important as that of population size and unmet need, then a relative weight of 0.5 would be 
assigned to the former, and a relative weight of 0.25 would be assigned to the two latters 
respectively. 
 In practice, this could involve a swing weighting or trade-off method, possibly implemented 
in combination with a “nominal-group technique”, according to which key stakeholders (as 
mentioned above) decide on the relative contribution of each criterion, perhaps through a 
paired-comparison process if many criteria are existent (Belton and Stewart, 2002; Dodgson 
et al., 2009; Walker et al., 2011).  
 
4.5. Producing a value index by combining individual scores and weights 
Assuming that criteria are mutually preference-independent from each other, and given that 
uncertainty does not formally need to be built into the model, a linear additive model 
procedure could be used for individual criteria scores and their relative weights to be 
combined through a weighted average of scores to produce “total value” (Keeney and Raiffa, 
1976; Dodgson et al., 2009; Phillips et al, 2011). Other more advanced types of modelling 
procedures also exist that could be applied depending on the model’s assumptions, allowing 
the weighted scores of the different criteria to interact with each other in a more complex 
manner, other than in a simple additive fashion (Keeney and Raiffa, 1976). 
Results would be examined, validated, and sensitivity analysis would be conducted to test the 
impact of different possible scores or weights on the overall value of the drug, thus testing 
inputs vagueness and possibly helping to resolve any existing disagreements between the 
various stakeholders. 
 
12 
 
4.6. Applying the methodology more widely and linking value assessment to coverage 
and/or pricing decisions.  
The result of such an MCDA would subsequently give evidence of the overall value of each 
drug option. Depending on the context of the health care system and the respective pricing 
and reimbursement policies in place, such a value metric could be applied in two possible 
ways: to inform either coverage/reimbursement decisions, or the price setting mechanism.  
Under the former application, a rational way forward could be to adopt a “value for money” 
or cost-effectiveness approach that takes into account the MCDA value scores and the costs 
of the corresponding options. Such a cost-effectiveness ranking of options would inform 
decision makers on how to most efficiently allocate resources by prioritising drugs with the 
best “value for money”.  
Under the latter application, drug candidates could be priced according to their value by 
setting a link between MCDA value index scores and the corresponding prices.  In practice 
this could take place through the application of comparative price rules, translating MCDA 
scores differences between the competing products into a pricing scale, most likely in 
combination with the development of a price index. The actual price differences would 
depend on the available health care and pharmaceutical budgets of the country per se, and 
possibly on other surrounding factors associated with the pricing and reimbursement system 
in place. 
 
5. Conclusion 
A new approach is needed for assessing the value of new medical technologies that takes into 
account a more comprehensive set of parameters than just the incremental cost per unit of 
additional therapeutic benefit. Such an approach could be conceptually and methodologically 
superior to the current HTA approaches mainly because of examining multiple, and 
seemingly necessary, criteria thus forming a “holistic” approach of complete assessment. In 
turn, inclusion, scoring and weighting of these parameters should be based on the expertise 
and opinions of a full spectrum of key stakeholders, thus trying to achieve an optimum 
balance across all the different, and possibly opposing, interests. A value index reflecting the 
overall value of a new medical technology could then be used to inform evidence-based 
coverage and/or pricing decisions thus helping to achieve an optimal allocation of resources.  
In conclusion, by developing an appropriate MCDA methodological framework for the 
context of HTA, the total value of new medical technologies could be transparently assessed 
using a clear, comprehensive, and explicit set of criteria. The results could then be applied as 
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a tool for consistent decision making that aims to maximise efficiency in resource allocation 
while improving health outcomes and sustaining future innovation. 
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